Inhibition of PDGFR can significantly reduce the activation of cancer-associated fibroblasts (CAFs), thereby decreasing the excessive deposition of the extracellular matrix and improving tumor tissue perfusion and drug permeability (24). This evidence concerns the gene PDGFRB and cancer.